Lemborexant Versus Sedative-Hypnotics in the Treatment of Insomnia: A Systematic Narrative Review
Sleep and Vigilance · 04.08.2026
DOI: 10.1007/s41782-026-00366-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sleep and Vigilance, online erschienen am 04.08.2026. Verfasst von Benjamin Holloway und 1 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St Vincent's Hospital Melbourne.
Themen: Schlaf
Abstract (Originalsprache)
Purpose
Sedative-hypnotics for insomnia carry risks of adverse effects and dependence. We reviewed how lemborexant, a dual orexin receptor antagonist (DORA), compares with sedative-hypnotics (benzodiazepines and z-drugs) in adults with insomnia across sleep, adverse events, dependence, and switching.
Methods
We conducted a PRISMA-guided systematic narrative review (not a meta-analysis; not prospectively registered), searching PubMed, Google Scholar, Embase, Cochrane CENTRAL, and PsycINFO from January 2000 (last searched 10 June 2026). Two reviewers independently screened and extracted data; risk of bias was assessed with Cochrane RoB 2 and ROBINS-I and certainty with GRADE, and synthesis followed SWiM.
Results
Sixteen reports (12 unique studies) were included. The only head-to-head efficacy comparator was zolpidem; no trial has compared lemborexant with a benzodiazepine or a non-zolpidem agent for insomnia efficacy. Against zolpidem, lemborexant improved objective polysomnographic sleep onset, maintenance, and efficiency (moderate certainty), although subjective sleep maintenance was mixed (zolpidem was superior on diary-reported wake after sleep onset at one month). At therapeutic doses it caused less next-day postural instability (moderate certainty), psychomotor/cognitive separation was clearest versus supratherapeutic zolpidem (low certainty). Falls and switching signals were of very low certainty, and abuse potential did not differ significantly from zolpidem (not lower).
Conclusion
Lemborexant is a promising alternative to zolpidem, with a favourable objective-sleep and next-day-safety profile (in older adults), but evidence against the broader sedative-hypnotic class is absent and most safety and switching signals are of low certainty; broader, long-term, head-to-head trials against benzodiazepines and other agents are needed.
Förderung
- St Vincent's Hospital Melbourne
Zitieren
APA
Holloway, B., & Sandrini, J. (2026). Lemborexant Versus Sedative-Hypnotics in the Treatment of Insomnia: A Systematic Narrative Review. Sleep and Vigilance. https://doi.org/10.1007/s41782-026-00366-6
Vancouver
Holloway B, Sandrini J. Lemborexant Versus Sedative-Hypnotics in the Treatment of Insomnia: A Systematic Narrative Review. Sleep and Vigilance. 2026. doi:10.1007/s41782-026-00366-6
BibTeX
@article{Holloway2026,
author = {Holloway, Benjamin and Sandrini, Jake},
title = {Lemborexant Versus Sedative-Hypnotics in the Treatment of Insomnia: A Systematic Narrative Review},
journal = {Sleep and Vigilance},
year = {2026},
doi = {10.1007/s41782-026-00366-6}
}
EUVIMED